Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| TP53 | 95% | TP53 mutation (high-grade serous) | cBioPortal (TCGA) |
| MUC16 (CA-125) | 80% | MUC16 expression | doi.org |
| CDH6 High-grade serous | 65-85% | IHC, any expression | Wikipedia |
| Mesothelin Serous | 60-70% | IHC, any expression | Wikipedia |
| Claudin 6 varies by antibody and cutoff | 50-60% | IHC positivity | |
| PARP ~20% germline/somatic BRCA | 50% | HRD-positive (BRCA or genomic scar) | Wikipedia |
| Folate receptor alpha MIRASOL eligibility; ~80% any expression | 35-40% | FRα-high (PS2+ in >=75% of cells) | Wikipedia |
| BRCA1 / BRCA2 (HRD) | 15-20% | Germline BRCA1/2; ~25% including somatic | Wikipedia |
| WEE1 TP53 mutation ~95% | 15-20% | CCNE1 amplification (dependency context) | cBioPortal (TCGA) |
| KRAS | 10-15% | Low-grade serous and mucinous | cBioPortal (TCGA) |
| ATR | n/a | Replication-stress context; no expression threshold | Wikipedia |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
8 cell lines, 2 mouse models and 7 repositories are listed for this cancer. See them →